DelveInsight’s IgG4 related Disease Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the IgG4 related Disease domain.
The IgG4 related Disease Pipeline Analysis report offers a comprehensive outlay of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for IgG4 related Disease emerging therapies. The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.
Some of the key highlights from the IgG4 related Disease Pipeline report:
- At present, there are no specific drugs available to cure the disease completely as the pathophysiology of the IgG4 related disease is not clear, however, research and development are going on to find effective therapeutics options against IgG4 related Disease.
- Currently, IgG4-related diseases exhibit a high medical unmet need, with many therapies in the pipeline the therapeutics market is expected to change significantly in the future.
- The prominent players strengthening the IgG4 related Disease pipeline include Viela Bio/Horizon Therapeutics, Xencor, Principia Biopharma, and many others.
- The emerging therapies in the IgG4-related diseases market include Inebilizumab, Obexelimab, Rilzabrutinib, and others. Few of the therapies are in the last stage of development and are expected to launch in the near future.
Request for Sample @ IgG4 related Disease Pipeline Insights and Outlook
Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition with a characteristic histopathological appearance that can affect multiple organs of the body. It mostly affects middle-aged to elderly individuals, however, children can also be affected. Similarly, males are found to be more affected than females.
There is no drug in the market to cure the disease, however, with many therapies in the pipeline the treatment scenario is expected to change in the coming years. As per, DelveInsight, the IgG4-Related Disease therapeutics market is further expected to increase in the coming future owing to factors such as rising prevalent population, technological advancements, and launch of potential therapies.
IgG4 related Disease Pipeline Analysis: Drug Profile
- Inebilizumab: Viela Bio/Horizon Therapeutics
Inebilizumab is a humanized monoclonal antibody designed to target and deplete CD19-expressing B cells. In October 2020, Viela Bio initiated a Phase 3, randomized, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease.
- Rilzabrutinib: Principia Biopharma
Principia Biopharma is working on Rilzabrutinib against three different disease indications (including IgG4-Related Disease). The therapy is currently in Phase II of the clinical stage. Rilzabrutinib against IgG4-RD can impact many of the driving features of the IgG4-Related Disease, including inflammation, allergic components, monocytes, macrophages, and B cells implicated in initiation and maintenance of disease.
Dive deeper to know more @ IgG4 related Disease therapeutics and drugs pipeline
Key Pipeline Therapies along with Companies
- Inebilizumab: Viela Bio/Horizon Therapeutics
- Rilzabrutinib: Principia Biopharma
And few others
IgG4 related Disease Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Intravenous
- Inhalation
- Sub-cutaneous
- By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
- Targets:
- Protease
- Immunomodulatory
- Multiple Kinase Inhibitor
- By Mechanism of Action
- Anti-CD 19
- Fc gamma receptor IIB antagonists
- Agammaglobulinaemia tyrosine kinase inhibitors
Got queries? Reach out for more information @ IgG4 related Disease Drug Pipeline Assessment
Scope of the Report
- Coverage: Global
- Key Market Players: Viela Bio, Horizon Therapeutics, Principia Biopharma, Xencor, and others.
- Key Pipeline Therapies: Obexelimab, Inebilizumab, Rilzabrutinib, and others.
Table of Content
|
1 |
Report Introduction |
|
2 |
IgG4 related Disease |
|
3 |
IgG4 related Disease Current Treatment Patterns |
|
4 |
IgG4 related Disease – DelveInsight’s Analytical Perspective |
|
5 |
Therapeutic Assessment |
|
6 |
IgG4 related Disease Late Stage Products (Phase-III) |
|
7 |
IgG4 related Disease Mid Stage Products (Phase-II) |
|
8 |
Early Stage IgG4 related Disease Products (Phase-I) |
|
9 |
IgG4 related Disease Pre-clinical Products and Discovery Stage Products |
|
10 |
Inactive Products |
|
11 |
Dormant Products |
|
12 |
IgG4 related Disease Discontinued Products |
|
13 |
IgG4 related Disease Product Profiles |
|
14 |
IgG4 related Disease Key Companies |
|
15 |
IgG4 related Disease Key Products |
|
16 |
Dormant and Discontinued Products |
|
17 |
IgG4 related Disease Unmet Needs |
|
18 |
IgG4 related Disease Future Perspectives |
|
19 |
IgG4 related Disease Analyst Review |
|
20 |
Appendix |
|
21 |
Report Methodology |
Know more of what’s covered in the IgG4 related Disease Pipeline Assessment report
Key Questions Answered in the IgG4 related Disease Report
- What are the current options for IgG4 related Disease treatment?
- How many companies are developing therapies for the treatment of IgG4 Related Diseases?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of IgG4 related Diseases?
- How many IgG4 related Disease emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of IgG4 related Disease?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the IgG4 related Disease market?
Request for a Webex demo @ IgG4 related Disease Drug Pipeline and get a walk-through of our report
Related Reports –
DelveInsight’ s IgG4-Related Disease- Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed understanding of historical and forecasted epidemiology as well as the market forecast in the 7MM.
IgG4-Related Disease Epidemiology Forecast
DelveInsight’s IgG4-Related Disease – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of IgG4-Related Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
Guillain-Barre Syndrome (GBS) Market
DelveInsight’s “Guillain-Barre Syndrome (GBS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Guillain-Barre Syndrome (GBS) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Neuromodulation Devices Market
DelveInsight’s ‘Neuromodulation Devices -Market Insights, Competitive Landscape, and Market Forecast – 2026’ report delivers an in-depth understanding of Neuromodulation Devices and the historical and forecasted Neuromodulation Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Healthcare Blogs By DelveInsight –
Chronic Respiratory Diseases (CRD) Treatment Market
Antibody-mediated Rejection Therapeutics Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Information:
Shruti Thakur info@delveinsight.com +1(919)321-6187
Tags:
, Menafn, IPS, Reportedtimes, iCN Internal Distribution, Extended Distribution, Research Newswire, English
Contact Information:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
The post IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others appeared first on Financial Market Brief.